Search research articles
Contact Us
Filters
Showing results (161-170 of 172) with videos related to
Page
of 18
Sort By:
Haematologica
|
July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
Ilaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
Blood
|
September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
Naranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Oncogene
|
April 12, 2011
OTX1 expression in breast cancer is regulated by p53
A Terrinoni, I S Pagani, I Zucchi, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Oncoscience
|
January 17, 2015
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia
Ilaria S Pagani, Orietta Spinelli, Elia Mattarucchi, et al.
Leukemia
|
November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
The Breast Journal
|
November 6, 2010
The mammary gland and the homeobox gene Otx1
Ilaria S Pagani, Alessandro Terrinoni, Laura Marenghi, et al.
Leukemia
|
October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
Haematologica
|
March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 172) with videos related to
Sort By:
Page
of 18
Haematologica
|
July 7, 2018
<i>BCR-ABL1</i> genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
Ilaria S Pagani, Phuong Dang, Ivar O Kommers, et al.
Blood
|
September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
Naranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Oncogene
|
April 12, 2011
OTX1 expression in breast cancer is regulated by p53
A Terrinoni, I S Pagani, I Zucchi, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Oncoscience
|
January 17, 2015
Genomic quantitative real-time PCR proves residual disease positivity in more than 30% samples with negative mRNA-based qRT-PCR in Chronic Myeloid Leukemia
Ilaria S Pagani, Orietta Spinelli, Elia Mattarucchi, et al.
Leukemia
|
November 27, 2019
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
The Breast Journal
|
November 6, 2010
The mammary gland and the homeobox gene Otx1
Ilaria S Pagani, Alessandro Terrinoni, Laura Marenghi, et al.
Leukemia
|
October 14, 2018
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, et al.
Haematologica
|
March 23, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, et al.
Page
of 18